Aster IVF uses next generation sequencing (NGS), a testing method that provides outstanding accuracy. Pre-implantation Genetic Screening (PGS) is performed by Aster IVF to screen for genetic defects in embryos prior to pregnancy. PGS is typically used with parents that are (or are assumed) to be genetically normal and want assurance that only genetically normal embryos are transferred following IVF.
Aster IVF screens for chromosomal abnormalities, which can result in aneuploidy, embryos having the incorrect number of chromosomes, and translocations, chromosomes that are incorrectly arranged. For example, an extra copy of chromosome 21 manifests as Down Syndrome. Once the embryos have been screened and deemed free of genetic defects, they can be placed in the uterus. Performing this pre-screening procedure may, under some circumstances, substitute for invasive procedures that sometimes occur during pregnancy such as chorionic villus sampling and amniocentesis. If a genetic defect is found during these post-conception procedures, parents are forced to make a difficult decision: whether to terminate a pregnancy or risk having a child with a genetic disease. Pre-screening procedures can avoid these difficult decisions. Aster IVF is one of the early adapters using next generation sequencing (NGS) technology for pre-implantation genetic diagnosis (PGD). NGS is far superior to real-time PCR techniques that are the current standard.
Next generation sequencing (NGS) combines the power of single mutation detection and complete 24-chromosome aneuploidy screening. Both tests are performed simultaneously on the same embryo.